Kolexia
Gross Emmanuel Oncologie radiothérapie
Gross Emmanuel
Oncologie radiothérapie
Clinique Chirurgicale De Martigues
Martigues, France
68 Activités
17 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de la prostate Métastase tumorale Récidive tumorale locale Leucémies Leucémie chronique lymphocytaire à cellules B Leucémie lymphoïde Tumeurs du sein Tumeurs prostatiques résistantes à la castration Métastase lymphatique

Collaborateurs

Voir plus
Pignot Geraldine
Pignot Geraldine
Centre Paoli-Calmettes, Marseille, France
Ducournau Aurelie
Ducournau Aurelie
Clinique Chirurgicale De Martigues, Martigues, France
Macagno Alban
Macagno Alban
Clinique Chirurgicale De Martigues, Martigues, France
Foa Cyril
Foa Cyril
Clinique Chirurgicale De Martigues, Martigues, France

Industries

Voir plus
Janssen
56 collaboration(s)
Dernière en 2023
AstraZeneca
17 collaboration(s)
Dernière en 2023
MSD
12 collaboration(s)
Dernière en 2023
Bayer
10 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
GETUG-AFU 22 Phase II Randomized Trial Evaluating Outcomes of Post-Operative Immediate Salvage Radiation Therapy with or without ADT for Patients with Persistently Elevated PSA Level
A Red Journal Special IssueOligometastasis, Part 2   01 décembre 2022
PEACE2: A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
Essai Clinique (Sanofi)   28 octobre 2022
P.35 Genetic newborn screening and digital technologies to accelerate rare disease diagnosis: The EU-IMI screen4Care project
Neuromuscular disorders : NMD   01 octobre 2022
interview docteur emmanuel gross
Youtube @ Onco Urovar   26 novembre 2021
Prognostic Risk Classification for Biochemical Relapse-Free Survival in Oligometastatic Recurrent Prostate Cancer Determined by Choline PET.
Clinical genitourinary cancer   16 mars 2021
Patterns of practice of androgen deprivation therapy combined to radiotherapy in favorable and unfavorable intermediate risk prostate cancer. Results of The PROACT Survey from the French GETUG Radiation Oncology group.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique   02 novembre 2020
404MO Clinical relevance of MIR27A rs895819 polymorphism and its interaction with DPYD variants for predicting grade 4-5 fluoropyrimidine (FP) toxicity (tox) in the FUSAFE individual patient data meta-analysis (IPD-MA)
Abstract Book of the ESMO Virtual Congress2020 19 – 21 September / 16 – 18 October 2020   01 septembre 2020
FUSAFE individual patient data meta-analysis (MA) to assess the performance of dihydropyrimidine dehydrogenase (DPD) gene polymorphisms for predicting grade 4-5 fluoropyrimidine (FP) toxicity
Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September – 1 October 2019, Barcelona, Spain   01 octobre 2019
Systemic treatments for high-risk localized prostate cancer.
Nature reviews. Urology   09 septembre 2019
Late Toxicity and Quality of Life from GETUG-AFU 22 Study: A Multicenter Randomized Phase II Trial Comparing Radiotherapy +/- 6 Months of Degarelix as a Salvage Treatment for Patients with Detectable PSA after Radical Prostatectomy
Proceedings of the Amercian Society for Radiation Oncology 61st Annual Meeting   01 septembre 2019